ASO Visual Abstract: Tumor-Infiltrating Lymphocytes (TILs) as a Biomarker of Abscopal Effect of Cryoablation in Breast Cancer-A Pilot Study

被引:1
|
作者
Khan, Sonia Y. [1 ]
Melkus, Michael W. [1 ]
Rasha, Fahmida [2 ]
Castro, Maribel [1 ]
Chu, Victoria [1 ]
Brandi, Luis [3 ]
Khan, Hafiz [4 ]
Gill, Harvinder Singh [5 ]
Pruitt, Kevin [2 ]
Rahman, Rakhshanda Layeequr [1 ,6 ]
机构
[1] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Dept Surg, Lubbock, TX 79430 USA
[2] Texas Tech Univ, Hlth Sci Ctr, Dept Immunol & Mol Microbiol, Lubbock, TX 79430 USA
[3] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Dept Pathol, Lubbock, TX 79430 USA
[4] Texas Tech Univ, Hlth Sci Ctr, Julia Jones Matthews Dept Publ Hlth, Lubbock, TX 79430 USA
[5] Texas Tech Univ, Dept Chem Engn, Lubbock, TX 79409 USA
[6] Texas Tech Univ, Hlth Sci Ctr, Breast Ctr Excellence, Lubbock, TX 79430 USA
关键词
D O I
10.1245/s10434-021-11240-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as an immunological biomarker. This experiment evaluates the role of TILs in distant tumors as a measure of abscopal effect from cryoablation of breast cancer. Methods: BALB/c mice underwent bilateral orthotopic transplant with 4T1-12B (triple-negative) cells. At 2 weeks, left tumors were treated by either resection (standard of care group) or cryoablation (intervention group) followed by resection of the distant right tumors 1 week posttreatment. TIL scores were calculated from hematoxylin and eosin-stained sections and phenotyped for cytotoxic T-lymphocyte (CTL) markers by immunofluorescence. Primarily resected tumors served as baseline (Tbaseline), whereas resected distant right-sided served as the readout for abscopal effect (AbsRes or AbsCryo). Mice were monitored for tumor recurrence and metastasis. Results: The AbsCryo had a significant mean (SD) increase in stromal (2.8 [1.1]%; p = 0.015) and invasive margin TILs (50 [12]%; p = 0.02) compared with TBaseline (1.0 [0]% and 31 [4.9]%, respectively). CTL phenotyping revealed a significant increase in mean (SD) CD8+ T cells (15.7 [12.1]; p = 0.02) and granzyme B (4.8 [3.6]; p = 0.048) for the AbsCryo compared with TBaseline (5.2 [4.7] and 2.4 [0.9], respectively). Posttreatment, the cryoablation group had no recurrence or metastasis, whereas the resected group showed local recurrence and lung metastasis in 40% of the mice. Postprocedure increase in TIL score of distant tumors was associated with decrease in tumor relapse (p = 0.02). Conclusions: Cryoablation induced a robust tumor-specific TIL response compared with resection, suggesting an abscopal effect leading to the prevention of cancer recurrence and metastasis. © 2022, The Author(s).
引用
收藏
页码:2928 / 2929
页数:2
相关论文
共 50 条
  • [21] Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer
    Huertas-Caro, Carlos A.
    Ramirez, Mayra A.
    Rey-Vargas, Laura
    Bejarano-Rivera, Lina Maria
    Ballen, Diego Felipe
    Nunez, Marcela
    Mejia, Juan Carlos
    Sua-Villegas, Luz Fernanda
    Cock-Rada, Alicia
    Zabaleta, Jovanny
    Fejerman, Laura
    Sanabria-Salas, Maria Carolina
    Serrano-Gomez, Silvia J.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [22] Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer
    Carlos A. Huertas-Caro
    Mayra A. Ramírez
    Laura Rey-Vargas
    Lina María Bejarano-Rivera
    Diego Felipe Ballen
    Marcela Nuñez
    Juan Carlos Mejía
    Luz Fernanda Sua-Villegas
    Alicia Cock-Rada
    Jovanny Zabaleta
    Laura Fejerman
    María Carolina Sanabria-Salas
    Silvia J. Serrano-Gomez
    Scientific Reports, 13
  • [23] Spatial organization of tumor-infiltrating lymphocytes (TILs) is prognostic for survival in triple negative breast cancer (TNBC)
    Patel, Sahil H.
    Corredor, German
    Yoder, Rachel
    Barrera, Cristian
    Castillo, Miluska
    Bernabe, Luis
    Staley, Joshua
    Stecklein, Shane
    Viswanath, Satish E.
    Castaneda, Carlos A.
    Sharma, Priyanka
    Madabhushi, Anant
    CANCER RESEARCH, 2023, 83 (07)
  • [24] The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer
    Ilgun, Ahmet Serkan
    Aktepe, Fatma
    Gonullu, Onur
    Kapucuoglu, Nilgun
    Yararbas, Kanay
    Alco, Gul
    Ozturk, Alper
    Celebi, Filiz Elbuken
    Erdogan, Zeynep
    Ordu, Cetin
    Unal, Caglar
    Duymaz, Tomris
    Soybir, Gursel
    Yavuz, Ekrem
    Tuzlali, Sitki
    Ozmen, Vahit
    FUTURE ONCOLOGY, 2022, 18 (29) : 3289 - 3298
  • [25] The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast
    Pruneri, G.
    Lazzeroni, M.
    Bagnardi, V.
    Tiburzio, G. B.
    Rotmensz, N.
    DeCensi, A.
    Guerrieri-Gonzaga, A.
    Vingiani, A.
    Curigliano, G.
    Zurrida, S.
    Bassi, F.
    Salgado, R.
    Van den Eynden, G.
    Loi, S.
    Denkert, C.
    Bonanni, B.
    Viale, G.
    ANNALS OF ONCOLOGY, 2017, 28 (02) : 321 - 328
  • [26] Emerging measurements for tumor-infiltrating lymphocytes in breast cancer
    Wu, Rongrong
    Horimoto, Yoshiya
    Oshi, Masanori
    Benesch, Matthew G. K.
    Khoury, Thaer
    Takabe, Kazuaki
    Ishikawa, Takashi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (06) : 620 - 629
  • [27] Clinical significance of tumor-infiltrating lymphocytes in breast cancer
    Stanton, Sasha E.
    Disis, Mary L.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [28] Tumor-infiltrating lymphocytes in triple negative breast cancer
    Zakhartseva, L. M.
    Yanovytska, M. O.
    PATHOLOGIA, 2020, (03): : 287 - 294
  • [29] Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A metaanalysis of 3771 patients
    Denkert, C.
    von Minckwitz, G.
    Darb-Esfahani, S.
    Heppner, B. Ingold
    Klauschen, F.
    Furlanetto, J.
    Pfitzner, B.
    Huober, J.
    Schmitt, W.
    Blohmer, J-U
    Kuemmel, S.
    Engels, K.
    Lederer, B.
    Schneeweiss, A.
    Hartmann, A.
    Jakisch, C.
    Untch, M.
    Hanusch, C.
    Weber, K.
    Loibl, S.
    CANCER RESEARCH, 2017, 77
  • [30] Neoadjuvant nivolumab/relatlimab or nivolumab/ ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs)
    Nederlof, I.
    Rolfes, A. L.
    Gielen, R. C. A. M.
    Awada, G.
    Dongen, M. V.
    Horlings, H. M.
    Van De Vijver, K.
    Drukker, C. A.
    Van Duijnhoven, F.
    Lopez-Yurda, M.
    Mandjes, I.
    Mann, R. M.
    Loo, C. E.
    Blank, C. U.
    Schumacher, T. N.
    Salgado, R. F.
    Kok, M.
    ANNALS OF ONCOLOGY, 2024, 35 : 1206 - 1206